A retrospective analysis of 738 adults with Ph+ALL who underwent allogeneic hematopoietic cell transplantation (HCT) found that pre-transplant imatinib had beneficial effects on overall survival, relapse, and non-relapse mortality compared to a non-imatinib cohort of HCT recipients. Patients between the ages of 16-59 received HCT between 1990 and 2010 and were reported to the Japan Transplant Registry. Five-year overall survival was significantly higher in the imatinib cohort than in the non-imatinib cohort: 59% vs. 38%, respectively; (p<0.001).
Mizuta S, et al. BloodChoose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Pre-Transplant Imatinib Benefits Adults with Ph+ ALL
Mar 2014